| Literature DB >> 343678 |
L B Seeff, E C Wright, H J Zimmerman, H J Alter, A A Dietz, B F Felsher, J D Finkelstein, P Garcia-Pont, J L Gerin, H B Greenlee, J Hamilton, P V Holland, P M Kaplan, T Kiernan, R S Koff, C M Leevy, V J McAuliffe, N Nath, R H Purcell, E R Schiff, C C Schwartz, C H Tamburro, Z Vlahcevic, R Zemel, D S Zimmon.
Abstract
Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors. Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included.Entities:
Mesh：
Substances：
Year: 1978 PMID： 343678 DOI： 10.7326/0003-4819-88-3-285
Source DB: PubMed Journal: Ann Intern Med ISSN： 0003-4819 Impact factor: 25.391